Amyris, Inc. (AMRS) Collaboration Reaches “Key Milestone” in Oncology Drug Development
Amyris (NASDAQ: AMRS) shares are ticking higher after the industrial bioscience company said its collaboration with “one of the world’s leading” pharmaceutical companies has resulted in the creation of a “robust, sensitive activity assay for an oncology target in a live yeast strain.” This high-throughput assay enables screening for chemical diversity found in nature using Amyris’s proprietary µPharm™ platform, with the potential to provide previously inaccessible molecule targets. The µPharm platform combines two powerful technologies that Amyris said can significantly accelerate and reduce the cost of new drug discovery. To view the full press release, visit: http://nnw.fm/9LkVH About Amyris Amyris…